38.57
+0.17(+0.44%)
Currency In USD
| Previous Close | 38.4 |
| Open | 38.8 |
| Day High | 39.16 |
| Day Low | 38.12 |
| 52-Week High | 39.54 |
| 52-Week Low | 21.62 |
| Volume | 3.17M |
| Average Volume | 3.13M |
| Market Cap | 7.32B |
| PE | -10.83 |
| EPS | -3.56 |
| Moving Average 50 Days | 34.27 |
| Moving Average 200 Days | 29.3 |
| Change | 0.17 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $1,400 as of May 05, 2025 at a share price of $38.57. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,250.24 as of May 05, 2025 at a share price of $38.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
GlobeNewswire Inc.
Apr 28, 2025 9:00 AM GMT
- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time to first event (all-cause morta
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
GlobeNewswire Inc.
Apr 22, 2025 11:30 AM GMT
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
GlobeNewswire Inc.
Mar 31, 2025 2:00 PM GMT
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysisThis profound treatment effect, due to the near-complete